Hydroxyurea to inhibit human immunodeficiency virus-1 replication

Frank Romanelli, Claire Pomeroy, Kelly M. Smith

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Treatment of human immunodeficiency virus (HIV) infection continues to be a challenge. Drug regimens that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor are now the standard of care. These regimens require strict patient adherence and have numerous adverse effects at a high cost, so clinicians must continue to explore other therapeutic options. Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV. We conducted a critical review of the literature to examine the utility of hydroxyurea-based drug combinations.

Original languageEnglish (US)
Pages (from-to)196-204
Number of pages9
JournalPharmacotherapy
Volume19
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Hydroxyurea to inhibit human immunodeficiency virus-1 replication'. Together they form a unique fingerprint.

  • Cite this